Benzoquinones

"Benzoquinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Benzene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.

Descriptor ID	D016227
MeSH Number(s)	D02.806.250
Concept/Terms	Benzoquinones Benzoquinones Benzodiones 1,4-Benzoquinones 1,4-Benzoquinones p-Benzoquinones 2,5-Cyclohexadiene-1,4-Diones 1,2-Benzoquinones 1,2-Benzoquinones o-Benzoquinones

Below are MeSH descriptors whose meaning is more general than "Benzoquinones".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Quinones [D02.806]
Benzoquinones [D02.806.250]

Below are MeSH descriptors whose meaning is related to "Benzoquinones".

Below are MeSH descriptors whose meaning is more specific than "Benzoquinones".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Benzoquinones" by people in this website by year, and whether "Benzoquinones" was a major or minor topic of these publications.

Bar chart showing 17 publications over 11 distinct years, with a maximum of 4 publications in 2003

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	0	1	1
1999	0	1	1
2000	0	2	2
2002	0	1	1
2003	0	4	4
2004	0	1	1
2005	0	1	1
2007	1	0	1
2008	1	1	2
2010	1	1	2
2012	1	0	1

Below are the most recent publications written about "Benzoquinones" by people in Profiles.

Judson PL, Al Sawah E, Marchion DC, Xiong Y, Bicaku E, Bou Zgheib N, Chon HS, Stickles XB, Hakam A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Chen DT, Lancaster JM. Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity. Int J Gynecol Cancer. 2012 Jul; 22(6):960-7.

View in: PubMed
Kang BH, Siegelin MD, Plescia J, Raskett CM, Garlick DS, Dohi T, Lian JB, Stein GS, Languino LR, Altieri DC. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin Cancer Res. 2010 Oct 01; 16(19):4779-88.

View in: PubMed
Torres MP, Ponnusamy MP, Chakraborty S, Smith LM, Das S, Arafat HA, Batra SK. Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies. Mol Cancer Ther. 2010 May; 9(5):1419-31.

View in: PubMed
Fiskus W, Rao R, Fernandez P, Herger B, Yang Y, Chen J, Kolhe R, Mandawat A, Wang Y, Joshi R, Eaton K, Lee P, Atadja P, Peiper S, Bhalla K. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood. 2008 Oct 01; 112(7):2896-905.

View in: PubMed
Smith MA, Morton CL, Phelps DA, Kolb EA, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Wu J, Houghton PJ. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jul; 51(1):34-41.

View in: PubMed
Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, DeLaCruz A, Curley T, Heller G, Larson S, Schwartz L, Egorin MJ, Rosen N, Scher HI. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res. 2007 Mar 15; 13(6):1775-82.

View in: PubMed
Vasilevskaya IA, O'Dwyer PJ. 17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines. Biochem Pharmacol. 2005 Aug 15; 70(4):580-9.

View in: PubMed
Vasilevskaya IA, Rakitina TV, O'Dwyer PJ. Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines. Mol Pharmacol. 2004 Jan; 65(1):235-43.

View in: PubMed
Rakitina TV, Vasilevskaya IA, O'Dwyer PJ. Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling. Cancer Res. 2003 Dec 15; 63(24):8600-5.

View in: PubMed
Luo J, Benovic JL. G protein-coupled receptor kinase interaction with Hsp90 mediates kinase maturation. J Biol Chem. 2003 Dec 19; 278(51):50908-14.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement